Close Menu

Regulus

Regulus Therapeutics has appointed Douglas Williams to its board of directors.

Mirna Therapeutics this week announced that it has closed a Series C round of financing, raising $34.5 million in what is the microRNA therapeutics field's biggest single round of private investment.

Shares of Regulus Therapeutics fell back near their already-reduced initial public offering level this week, suggesting that Wall Street may be less willing to embrace microRNA therapeutics than may have been anticipated.

Regulus Therapeutics, the microRNA drugs joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, this week disclosed that it is pricing its initial public offering of 11.25 million shares at $4 a share, for a total value of $45 million.

This article has been updated from a previous version to include background on previous IPOs in the RNAi/microRNA market.

Regulus Therapeutics, the microRNA drug joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, has filed with US regulators to begin selling its shares on the public market.

Regulus Therapeutics this week announced that it has formed a strategic alliance with AstraZeneca to discover, develop, and commercialize microRNA therapeutics against three exclusive targets.

NEW YORK (GenomeWeb News) – Regulus Therapeutics, a developer of microRNA-based therapeutics, announced after the close of the market Wednesday that it has signed a deal with Biogen Idec to identify blood-borne miRNA biomarkers for multiple sclerosis.

Title: Detection of Nucleic Acids
Patent Number: 8,206,904
Filed: June 1, 2007
Lead Inventor: Hatim Allawi, Third Wave Technologies

Regulus Therapeutics has appointed Bruce Carter to its board of directors.

Pages

ScienceInsider reports that rude and unprofessional paper reviewers are common and can have harmful effects.

The US Senate has confirmed Stephen Hahn as the next commissioner of the Food and Drug Administration, according to the New York Times.

CNBC reports Apple is partnering with Color Genomics to offer its employees free DNA screening for disease.

In Science this week: researchers use CRISPR tool to find gut microbiome molecules involved in immunity, and more.